Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

Colorectal

E112: Peritoneal Metastasis Originated from Colorectal Cancer: Long-term Follow-up Results at a Single Institution in Turkey

Introduction:

This study aimed to examine the results of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis (PM) of colorectal cancer(CRC).

Methods:

This study aimed to examine the results of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis (PM) of colorectal cancer(CRC).

Results: The mean peritoneal cancer index was 20±8 (1 ~ 36), and complete cytoreduction was possible in 67 (46%) patients. Patients Characteristics are given in Table 1.

Multivariate analysis showed that mucinous pathology, nodal involvement, PCI more than 18  CC score KRAS and BRAF mutation are prognostic factors for survival (Table 2).

The overall 2- and 5-year survival rates were 36% and 27%, respectively. Patients with complete cytoreduction had a median survival period of 28 months, which was significantly longer than that for patients with incomplete cytoreduction (6 months) (P < 0.001).

The 5-year survival rate for patients with complete cytoreduction was 21.4%, and 15 patients were still alive without disease.

 

 

 

Conclusions:

CRS and HIPEC show a 5-year survival rate of 21.4% in patients with PM of colorectal cancer. Long-term survival can be achieved in subgroup of these patients.

Learning Objectives:

  • Peritoneal metastasis of Colorectal Cancer can be treated with cytoreductive surgery and HIPEC
  • Selection of the cases is the most important part of this treatment option
  • Prognosis of this disease depend on the patients characteristics as well as the hints of the treatment technique